Rainbow Extension Study
| Status: | Recruiting |
|---|---|
| Conditions: | Ocular, Ocular, Women's Studies |
| Therapuetic Areas: | Ophthalmology, Reproductive |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/5/2018 |
| Start Date: | June 16, 2016 |
| End Date: | October 31, 2022 |
| Contact: | Novartis Pharmaceuticals |
| Email: | novartis.email@novartis.com |
| Phone: | 1-888-669-6682 |
RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
The purpose of this study is to evaluate the long term efficacy and safety of intravitreal
ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy
of prematurity (ROP) in the core study CRFB002H2301
ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy
of prematurity (ROP) in the core study CRFB002H2301
Inclusion Criteria:
- The patient successfully completed the core study CRFB002H2301
- The patient received study treatment in both eyes at baseline of study CRFB002H2301
Exclusion Criteria:
- Patient has a medical condition or personal circumstance which precludes study
participation or compliance with study procedures, as assessed by the Investigator
- Patient has been discontinued from the core study CRFB002H2301 at any time
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials